Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Apr;64(4):831-842.
doi: 10.1111/epi.17535. Epub 2023 Mar 1.

A phase 1 open-label trial evaluating focused ultrasound unilateral anterior thalamotomy for focal onset epilepsy

Vibhor Krishna  1 , Jesse Mindel  2 , Francesco Sammartino  3 , Cady Block  4 , Alok Kumar Dwivedi  5 , Jamie J Van Gompel  6 , Nathan Fountain  7 , Robert Fisher  8
Affiliations
Clinical Trial

A phase 1 open-label trial evaluating focused ultrasound unilateral anterior thalamotomy for focal onset epilepsy

Vibhor Krishna et al. Epilepsia. 2023 Apr.

Abstract

Objective: Focused ultrasound ablation (FUSA) is an emerging treatment for neurological and psychiatric diseases. We describe the initial experience from a pilot, open-label, single-center clinical trial of unilateral anterior nucleus of the thalamus (ANT) FUSA in patients with treatment-refractory epilepsy.

Methods: Two adult subjects with treatment-refractory, focal onset epilepsy were recruited. The subjects received ANT FUSA using the Exablate Neuro (Insightec) system. We determined the safety and feasibility (primary outcomes), and changes in seizure frequency (secondary outcome) at 3, 6, and 12 months. Safety was assessed by the absence of side effects, that is, new onset neurological deficits or performance deterioration on neuropsychological testing. Feasibility was defined as the ability to create a lesion within the anterior nucleus. The monthly seizure frequency was compared between baseline and postthalamotomy.

Results: The patients tolerated the procedure well, without neurological deficits or serious adverse events. One patient experienced a decline in verbal fluency, attention/working memory, and immediate verbal memory. Seizure frequency reduced significantly in both patients; one patient was seizure-free at 12 months, and in the second patient, the frequency reduced from 90-100 seizures per month to 3-6 seizures per month.

Significance: This is the first known clinical trial to assess the safety, feasibility, and preliminary efficacy of ANT FUSA in adult patients with treatment-refractory focal onset epilepsy.

Trial registration: ClinicalTrials.gov NCT03417297.

Keywords: anterior nucleus; clinical trial; epilepsy; focused ultrasound; thalamotomy.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Hauser WA. The natural history of drug resistant epilepsy: epidemiologic considerations. New York: Elsevier Science Publisher; 1992.
    1. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548-54.
    1. Zack MM, Kobau R. National and State estimates of the numbers of adults and children with active epilepsy - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:821-5.
    1. Banerjee PN, Filippi D, Allen HW. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009;85:31-45. Research Support, N.I.H., Extramural Review.
    1. Cascino GD. When drugs and surgery don't work. Epilepsia. 2008;49(Suppl 9):79-84.

Publication types

Associated data

LinkOut - more resources